Ayala Pharmaceuticals Inc (ADXS)

[Traderbx]

Checkpoint Inhibitors guidelines (restrictions) developed by ASCO & NCCN:

"Patients who receive immune checkpoint inhibitors, however, may experience a unique set of side effects. These side effects can involve multiple organs of the body, and although they are typically mild, sometimes severe, irreversible, or even life-threatening reactions can occur."

Key guideline recommendations:

In general, checkpoint inhibitors can be continued with close monitoring for mild (grade 1) toxicities, with the exception of neurologic and some hematologic toxicities.

For moderate (grade 2) toxicities, checkpoint inhibitors should be held until symptoms and/or lab values revert to grade 1 levels or lower. Corticosteroids may be offered.

For severe (grade 3) toxicity, patients should receive high-dose corticosteroids for at least 6 weeks. Extreme caution when restarting immunotherapy after a grade 3 toxicity is recommended, if it is restarted at all.

In general, very severe (grade 4) toxicity necessitates stopping checkpoint inhibitor therapy permanently.

Consult the guidelines directly for more specific recommendations depending on which organ is affected.



http://www.pharmacytimes.com/news/understanding-managing-immunotherapy-side-effects?utm_content=buffer420ee&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer